source
- Merck and Daiichi withdraw lung cancer ADC filing after FDA says data insufficientMerck and Daiichi Sankyo have pulled their application for accelerated approval of a B7-H3-directed antibody-drug conjugate aimed at extensive-stage small cell lung cancer. The FDA indicated that…
- Operational talent, not just science, will drive next biopharma breakthroughsThe piece points out that while breakthrough science, founders and venture funding are typical markers of progress, the real test is moving a promising therapy through GMP production, quality syste…